Recent Posts
- MicroRNA-Mediated Metastasis Suppression
- A New Explanation Of ‘Asian Paradox’
- Toward Bold New Anti-cancer Medicines
- Celsion And Yakult Honsha Announce Treatment Of First Patient In Japan In Celsion’s Global Phase III ThermoDox(R) Trial For Primary Liver Cancer
- $6.5 Million Gift To UCSF From Irwin And Joan Jacobs For Head And Neck Cancer Research
Random Posts
- Free Cancer Information CDs Now Available
- American Association For Cancer Research Announces New Editor-in-Chief Of Cancer Research
- Is Your Environment Damaging Your Health? New Center Aims To Find Out
- Sensitivity To NNKOAc Is Associated With Renal Cancer Risk
- Acrylamide Gets Clean Bill on Lung Cancer
- Novel Therapy May Prove Effective In Treatment Of 30 Percent Of Cancers
- Second European Country To Commence Cerepro(R) Treatment On Named Patient Basis, England
- SuperGen's MP-470 Demonstrates Clinical Benefit In Lung Cancer Patients
- Bone Cancer Research Trust Calls For New Treatments For Bone Cancer
- First Baby Is Born After A New Technique
Prescription Cancer Drugs
AstraZeneca Withdraws Its Marketing Authorisation Application For Zactima (vandetinib), Europe
Posted by: admin in Prescription Cancer Drugs on November 06th, 2009
The European Medicines Agency has been formally notified by AstraZeneca of its decision to withdraw its application for a centralised marketing authorisation for the medicine Zactima (vandetinib), 100 mg film-coated tablets.
Zactima was expected to be used in combination with chemotherapy, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received prior anticancer therapy.
The application for the marketing authorisation for Zactima was submitted to the Agency on 30 June 2009. At the time of the withdrawal, it was under review by the Agency’s Committee for Medicinal Products for Human Use (CHMP).
In its official letter, the company stated that the withdrawal of the application was based on the preliminary comments from the Rapporteur and Co-Rapporteur, which indicate that at this point in time the Committee would be unlikely to conclude on a favourable benefit-risk balance for the product in the treatment of NSCLC in combination with chemotherapy.
More information about Zactima and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency’s website after the next CHMP meeting of 16-19 November 2009.
Notes
1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage.
Source
EMEA
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.